文献速递甲状腺疾病性腺与生殖内分泌

妊娠期促甲状腺激素水平在2.5至10 mIU/L之间的孕妇左甲状腺素治疗:一项倾向评分匹配分析

Levothyroxine Treatment in Pregnant Women with Thyrotropin Levels Ranging Between 2.5 and 10 mIU/L: A Propensity Score Matched Analysis.
PubMed 文献 · Thyroid · 2024-05-09

该回顾性队列数据分析纳入4370例孕早期促甲状腺激素(TSH)2.5-10 mIU/L且游离甲状腺素正常的中国孕妇,其中1342例接受左甲状腺素(LT4)治疗、3028例未治疗。1:1倾向评分匹配后显示,LT4治疗与妊娠丢失风险降低(RR=0.528,95%CI:0.344-0.812)及小于胎龄儿风险升高(RR=1.595,95%CI:1.023-2.485)显著相关。亚组分析提示上述效应主要来自甲状腺过氧化物酶抗体(TPOAb)阴性者;在TPOAb阳性且TSH 2.5-4.0 mIU/L的孕妇中,LT4治疗与早产风险升高相关(RR=2.214,95%CI:1.016-4.825)。

要点

  • 孕早期TSH 2.5-10 mIU/L孕妇中,LT4治疗与妊娠丢失风险降低相关(RR=0.528)。
  • LT4治疗与小于胎龄儿风险升高相关(RR=1.595),效应主要来自TPOAb阴性者。
  • TPOAb阳性且TSH 2.5-4.0 mIU/L者中,LT4治疗与早产风险升高相关(RR=2.214)。

核心结论

  • 在TSH 2.5-10 mIU/L的孕妇中,LT4治疗与妊娠丢失风险降低及小于胎龄儿风险升高显著相关。
  • 在TPOAb阳性且TSH 2.5-4.0 mIU/L的孕妇中,LT4治疗组观察到早产风险升高。

研究设计与样本

  • 回顾性分析回顾性和前瞻性收集的队列数据,纳入孕早期TSH 2.5-10 mIU/L且游离甲状腺素正常(11.8-18.4 pmol/L)的中国孕妇。
  • 共纳入4370例孕妇,其中1342例接受LT4治疗,3028例未接受。
  • 采用多变量逻辑回归模型进行1:1最近邻倾向评分匹配(卡钳距离0.02),得到668对个体。
  • 使用多变量调整的改良泊松回归估计LT4治疗对不良妊娠结局的相对风险(RR)和95%置信区间(CI)。
  • 按TPOAb状态(阴性或阳性)和TSH水平(2.5-4.0 mIU/L为高正常组,4.0-10.0 mIU/L为亚临床甲状腺功能减退症组)同时分层进行四个亚组分析。

主要发现

  • 倾向评分匹配后,LT4治疗与妊娠丢失风险降低显著相关(RR=0.528,95%CI:0.344-0.812)。
  • LT4治疗与小于胎龄儿风险升高显著相关(RR=1.595,95%CI:1.023-2.485)。
  • 亚组分析提示LT4治疗的上述效应主要来自TPOAb阴性参与者。
  • 在TPOAb阳性且TSH 2.5-4.0 mIU/L的孕妇中,LT4治疗与早产风险升高相关(RR=2.214,95%CI:1.016-4.825)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To clarify the association between levothyroxine (LT4) treatment and various adverse pregnancy outcomes in pregnant women with thyrotropin (TSH) levels ranging between 2.5 and 10.0 mIU/L in the first trimester, stratified according to thyroid peroxidase antibody (TPOAb) positivity and TSH level. Methods: This retrospective analysis of retrospectively and prospectively collected cohort data included Chinese pregnant women with TSH levels of 2.5-10 mIU/L and normal free thyroxine levels (11.8-18.4 pmol/L) in the first trimester. All participants were followed up until the completion of pregnancy, and information on LT4 treatment, pregnancy complications, and pregnancy outcomes was recorded. A 1:1 nearest-neighbor propensity score matching (PSM) between the LT4-treated and - untreated groups with a caliper distance of 0.02 was performed using a multivariable logistic regression model. Multivariable-adjusted modified Poisson regression was used to estimate the relative risk (RR) and 95% confidence interval (CI) of LT4 treatment for adverse pregnancy outcomes. Subgroup analyses were also performed in four subgroups simultaneously stratified by TPOAb status (negative or positive) and TSH levels (2.5-4.0 mIU/L as high-normal group and 4.0-10.0 mIU/L as SCH group). The study was registered in the Chinese Clinical Trial Registry (ChiCTR2100047394). Results: Among the 4,370 pregnant women in the study, 1,342 received LT4 treatment and 3,028 did not. The 1:1 PSM yielded 668 pairs of individuals and revealed that LT4 treatment was significantly associated with a decreased risk of pregnancy loss (RR = 0.528, 95% CI: 0.344-0.812) and an increased risk of small-for-gestational-age infants (RR = 1.595, 95% CI: 1.023-2.485). Subgroup analyses suggested that the above effects of LT4 treatment were mainly from TPOAb-negative participants. LT4 treatment was associated with an increased risk of preterm birth (RR = 2.214, 95% CI: 1.016-4.825) in TPOAb-positive pregnant women with high-normal TSH levels. Conclusion: LT4 treatment was significantly associated with a lower risk of pregnancy loss and a higher risk of small-for-gestational-age infants in pregnant women with TSH levels of 2.5-10 mIU/L. An increased risk of preterm birth was observed in the LT4-treated group among TPOAb-positive participants with TSH levels of 2.5-4.0 mIU/L.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Gao S, Wang X, Zhao R, et al. Levothyroxine Treatment in Pregnant Women with Thyrotropin Levels Ranging Between 2.5 and 10 mIU/L: A Propensity Score Matched Analysis. Thyroid. 2024. PMID: 38666684. doi:10.1089/thy.2023.0662

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。